AprilHarlynnTeitelbaumMD

PubMed

• 2 citations
  Healthcare costs related to adverse events in hepatocellular carcinoma treatment: A retrospective observational claims study.
  Lincy S. Lal, Abdalla Aly, Lisa B. Le, Susan Peckous, Brian Seal, April Teitelbaum> ;Cancer Reports. 2021 Sep 7
• 76 citations
  An Evaluation of Algorithms for Identifying Metastatic Breast, Lung, or Colorectal Cancer in Administrative Claims Data.
  Joanna L. Whyte, Nicole M. Engel-Nitz, April Teitelbaum, Gabriel Gomez Rey, Joel Kallich> ;Medical Care. 2015 Jul 1
• 4 citations
  Diagnostic testing managed by hematopathology specialty and other laboratories: costs and patient diagnostic outcomes
  Nicole M. Engel-Nitz, Benjamin Eckert, Rui Song, Priyanka Koka, Erin M. Hulbert, Jeffrey McPheeters, April Teitelbaum> ;BMC Clinical Pathology. 2014 Apr 27
• 182 citations
  Health Care Costs for Patients With Cancer at the End of Life
  Benjamin Chastek, Carolyn Harley, Joel Kallich, Lee N. Newcomer, Carly J. Paoli, April Teitelbaum> ;Journal of Oncology Practice. 2012 Jul 3
• 12 citations
  The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costs.
  Carolina M. Reyes, Stacey DaCosta Byfield, R. Linke, Sacha Satram-Hoang, A. Teitelbaum> ;Melanoma Research. 2013 Apr 1
• 58 citations
  Health Care Costs and Resource Utilization, Including Patient Burden, Associated With Novel-Agent-Based Treatment Versus Other Therapies for Multiple Myeloma: Findings...
  April Teitelbaum, Abbie Ba-Mancini, Hui Huang, Henry J. Henk> ;The Oncologist. 2013 Jan 1
• 20 citations
  Economic burden of resected squamous cell carcinoma of the head and neck in a US managed-care population.
  Mayur M. Amonkar, Benjamin Chastek, Navendu Samant, April Teitelbaum> ;Journal of Medical Economics. 2011 Jul 7
• Monitoring response and treatment outcome in patients with chronic phase chronic myeloid leukemia (CML) treated with imatinib.
  Teitelbaum A, Spencer D, Bollu VK, Chastek B, Coombs J, Kulakodlu M, Morlock R> ;J. Clin. Oncol.. 2011-05-20
• Thrombopoietin receptor agonist (TPO-RA) usage and treatment patterns among patients with chronic immune thrombocytopenic purpura (cITP) in a large U.S.-managed care p...
  Engel-Nitz NM, Wang PF, Gomez Rey G, Teitelbaum A> ;J. Clin. Oncol.. 2011-05-20
• Costs and utilization of oncology health care services at the end of life.
  Chastek B, Harley CR, Kallich JD, Newcomer LN, Paoli CJ, Teitelbaum A> ;J. Clin. Oncol.. 2011-05-20
• The burden of metastatic melanoma (mM): Treatment patterns, healthcare use, and costs.
  Reyes C, DaCosta Byfield S, Satram-Hoang S, Teitelbaum AH> ;J. Clin. Oncol.. 2011-05-20
• 45 citations
  Small noncleaved follicular center cell (FCC) lymphoma: Burkitt and non-Burkitt variants in the United States. I. Clinical features†
  Alexandra M. Levine, Zdena Pavlova, Ann W. Pockrosrn, John W. Parker, April H. Teitelbaum, Annlia Paganini-Hill, Darleen R. Powars, Robert J. Lukes, Donald I. Feinstein> ;Cancer. 1983 Sep 15
• 2 citations
  Antithrombin III and anti-activated factor X activity in patients with acute promyelocytic leukemia and disseminated intravascular coagulation treated with heparin.
  R M Sandler, H A Liebman, M J Patch, A Teitelbaum, A M Levine, D I Feinstein> ;Cancer. 1983 Feb 15
• 17 citations
  Antithrombin III and anti-activated factor X activity in patients with acute promyelocytic leukemia and disseminated intravascular coagulation treated with heparin.
  R M Sandler, H A Liebman, M J Patch, A Teitelbaum, A M Levine, D I Feinstein> ;Cancer. 1982 Nov 15
• Join now to see all